NEW YORK (AP) _ Stemline Therapeutics Inc. (STML) on Wednesday reported a loss of $14.6 million in its first quarter.
The New York-based company said it had a loss of 67 cents per share.
The results fell short of Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for a loss of 47 cents per share.
The biopharmaceutical company posted revenue of $299,400 in the period. Its adjusted revenue was $299,000.
Stemline Therapeutics shares have declined 27 percent since the beginning of the year. In the final minutes of trading on Wednesday, shares hit $7.85, a rise of 38 percent in the last 12 months.
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on STML at https://www.zacks.com/ap/STML
Keywords: Stemline Therapeutics, Earnings Report